



Karyopharm Therapeutics
Investor Relations Department
85 Wells Ave, 2nd floor
Newton, MA 02459
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: KPTI

Last Trade:	11.43
Trade Time:	4:00 PM ET Oct 17, 2017
Change:	0.05 (+0.439%)
Day Range	11.23 - 11.74
52-Week Range	6.27 - 14.63
Volume	289,094

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflamma... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 12, 2017

[Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia](#)

Sep 20, 2017

[Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma](#)

Sep 12, 2017

[Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Sep 8, 2017

[Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting](#)

Aug 30, 2017

[Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

